SUPNSUPERNUS PHARMACEUTICALS, INC.vs its industry peers
A metric-by-metric comparison of SUPERNUS PHARMACEUTICALS, INC. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPN본 종목 | $2.5B#6 | — | 2.4x#1 | 3.5x#2 | 8.6%#6 | -152.2%#13 | -8.7%#2 | -3.7%#2 | -5.0%#2 | — | -3.6%#4 | — |
| PGEN | $2.8B#1 | — | 63.6x#13 | 286.0x#8 | 146.7%#2 | -98.6%#11 | -1141.1%#8 | -575.1%#13 | -91.2%#9 | — | — | — |
| IMNM | $2.7B#2 | — | 5.2x#8 | 395.0x#9 | -23.2%#8 | 27.5%#1 | -3228.8%#9 | -40.4%#8 | -72.8%#8 | — | — | — |
| IRON | $2.7B#4 | — | 4.1x#5 | — | — | -94.0%#9 | — | -32.9%#7 | -39.0%#4 | — | — | — |
| NRIX | $2.7B#3 | — | 6.6x#10 | 31.7x#3 | 54.0%#4 | -36.6%#6 | -340.2%#5 | -65.7%#11 | — | — | — | — |
| MLYS | $2.5B#5 | — | 4.6x#7 | — | — | 13.0%#2 | — | -28.1%#6 | -41.3%#5 | — | — | — |
| VRDN | $2.5B#7 | — | 3.8x#4 | 35.1x#4 | 23359.9%#1 | -26.9%#5 | -512.9%#6 | -51.7%#10 | -54.5%#6 | — | — | — |
| HRMY | $2.5B#8 | 13.7x#1 | 2.5x#2 | 2.8x#1 | 21.5%#5 | 9.1%#4 | 24.0%#1 | 15.9%#1 | 25.5%#1 | 4#1 | 32.4%#3 | — |
| VERA | $2.4B#9 | — | 5.9x#9 | — | — | -96.9%#10 | — | -73.5%#12 | -72.7%#7 | — | 36.8%#1 | — |
| NKTR | $2.3B#10 | — | 2.6x#3 | 42.2x#5 | -43.9%#9 | -37.8%#8 | -253.7%#4 | -18.2%#3 | -14.0%#3 | — | 33.6%#2 | — |
| SLS | $2.3B#11 | — | 16.9x#12 | — | -100.0%#10 | 13.0%#3 | — | -19.5%#5 | — | — | — | — |
| OCUL | $2.2B#13 | — | 4.3x#6 | 43.0x#6 | -18.5%#7 | -37.4%#7 | -519.8%#7 | -51.1%#9 | — | — | — | — |
| PVLA | $2.2B#12 | — | 10.3x#11 | 52.3x#7 | 65.3%#3 | -139.3%#12 | -90.2%#3 | -19.2%#4 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice